X4 Pharmaceuticals reported a quarterly loss of $0.22 per share, beating the Zacks consensus loss of $0.36 by $0.14. The loss represents a $5.79 improvement year-over-year from a $6.01 loss a year ago, signaling significant earnings stabilization. The print is modestly supportive for the stock and is likely to move the share price in the single-digit percent range absent new guidance.
X4 Pharmaceuticals reported a quarterly loss of $0.22 per share, beating the Zacks consensus loss of $0.36 by $0.14. The loss represents a $5.79 improvement year-over-year from a $6.01 loss a year ago, signaling significant earnings stabilization. The print is modestly supportive for the stock and is likely to move the share price in the single-digit percent range absent new guidance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
